Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

Completed · Phase 3

Conditions studied: Anterior Uveitis

In brief

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Key facts

Study ID

NCT02517619

Run by

Eyegate Pharmaceuticals, Inc.

People needed

251

Starts

2016-01-16

Expected to finish

2018-05-29

Last updated by the study team

2018-07-26

Who can join

Age: 12 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an AC cell count of ≥ 11 cells
• Receive, understand, and sign a copy of the written informed consent form
• Be able to return for all study visits and willing to comply with all study-related instructions

Where it is running

• Virginia Eye Consultants — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.